Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

BUY
$3.22 - $4.86 $322,000 - $486,000
100,000 New
100,000 $418,000
Q2 2022

Aug 15, 2022

BUY
$8.27 - $18.43 $827,000 - $1.84 Million
100,000 New
100,000 $1.13 Million

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $78.9M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Maso Capital Partners LTD Portfolio

Follow Maso Capital Partners LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maso Capital Partners LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maso Capital Partners LTD with notifications on news.